Drug intelligence / Profile preview

Sorafenib + OSI-906

Development stage: Discontinued
Lead developer: Bayer Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of two distinct drugs. Sorafenib is a multikinase inhibitor that targets several serine/threonine and receptor tyrosine kinases involved in tumor growth and angiogenesis. OSI-906 (linsitinib) is a dual inhibitor of insulin-like growth factor-1 receptor (IGF1R) and insulin receptor (IR). The combination has been studied in clinical trials for advanced hepatocellular carcinoma.

Targets

INSR (Insulin receptor)ABCG2 (Breast cancer resistance protein)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))ABCC10 (Multidrug resistance-associated protein 7)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on Sorafenib + OSI-906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sorafenib + OSI-906.

Explore the full profile